New Developments At Roberts
Roberts Pharmaceutical has received approval from the US Food and Drug Administration to sell its Pro-Amatine (midodrine HCl) tablets without promotion for the treatment of orthostatic hypotension associated with autonomic failure of unrestricted etiology.
The company reports that distribution of the compound, which is still classed as an investigational drug, is an acknowledgement by the FDA of its utility. The product has already received regulatory approval in Canada (as Amatine) and Ireland (as Midon).
Two New Agreements Signed Roberts has also signed two new agreements with Merck & Co and Columbia Laboratories. The first of these is an exclusive marketing, sales and distribution deal for Noroxin (norfloxacin), a broad-spectrum antibiotic indicated for the treatment of urinary tract infections. Roberts will assume all marketing, pricing and promotional activities for the drug, and as a result will increase its US sales force by 30%-40% to actively promote it. Terms of the deal were not disclosed.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze